Aditxt Said On April 26 Received Notice From Evofem That Evofem Was Exercising Its Right To Terminate Merger Agreement As Result Of Co's Failure To Provide Initial Parent Equity Investment
-8-K
-8-K
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
3/4/2022 | $0.50 → $0.53 | Underweight | Morgan Stanley | |
11/16/2021 | $2.50 → $2.00 | Buy | HC Wainwright & Co. | |
10/21/2021 | $4.00 → $2.50 | Buy | HC Wainwright & Co. | |
10/14/2021 | $0.80 | Equal-Weight → Underweight | Morgan Stanley | |
8/12/2021 | $3.00 → $1.00 | Equal-Weight | Morgan Stanley |
Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously
Morgan Stanley downgraded Evofem Biosciences from Equal-Weight to Underweight and set a new price target of $0.80
Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Equal-Weight and set a new price target of $1.00 from $3.00 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $4.00 from $7.00 previously
HC Wainwright reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $7.00 from $8.00 previously
HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $7.00 from $8.00 previously
Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy
4 - Evofem Biosciences, Inc. (0001618835) (Issuer)
4 - Evofem Biosciences, Inc. (0001618835) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company's wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie's appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business ("B2B") and direct-to-consumer ("DTC") clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. "Naming Ernie as
SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Bioscien
SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Mr. Altro brings over 25 years of financial and operational experience including corporate restructuring, public accounting and executive management, and consulting, primarily in a leadership rol
AditxtScore™ continued driving revenue growth in 2022 by adding to its expanding customer base of large physician networks, healthcare systems, independent laboratories, and employer-sponsored programs. Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt's second program, AditxtScore™, through future strategic revenue and growth-oriented transactions. Anthony Voorhies, currently the head of the AditxtScore™ division, will s
Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for ty
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to six independent directors. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Now more than ever, this is the time to align and support organizations like Evofem with a sustainable future, which are dedicated to impr
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra
Fedasz will Focus on Opening New Markets for Evofem's First - and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric acid, and potassium bitartrate)SAN DIEGO, April 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem, Karina will oversee the company's business development, product and pipeline portfolios, new business ventures, and the advancement of access partnerships around the world. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
Aditxt, Inc. ("Aditxt, or the "Company"). (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal Accounting Officer of Aditxt, has been appointed as CFO. As CFO of Aditxt since July 2020, Ms. Pankovcin, along with the Company's CEO and executive team, has effectively managed the Company's growth as it became publicly traded on
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. "As a new independent director of Aditxt's board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals," said Amro Albanna, co-founder and CEO of Aditxt. "We look forward to working with Dr. Chung as we establish our portfolio of fi
SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe
This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women's health, spanning endometriosis to ovarian cancer, and in men's health starting with prostate cancer Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired MDNA Life Sciences Inc.'s ("MDNA") proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta's dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. Th
— On track to achieve third consecutive year of revenue growth – — Third consecutive quarter of favorable sales and marketing expense as a percentage of net sales — — Reduced loss from operations by 81% vs. Q3 2022 — SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> $5.1 million in net product sales of Phexxi® (la
— On track to achieve third consecutive year of revenue growth – — Second consecutive quarter of favorable net product sales to sales and marketing expense ratio — — Reduced total operating expenses 68% — — Decreased loss from operations by 70% — SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2023. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "This marks the second consecutive quarter in which our
-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to positive EBITDA -- SAN DIEGO, June 16, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA break-even by year-end 2023 -- SAN DIEGO, April 28, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), has reported financial results for the year ended December 31, 2022. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Highlights include
-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Date: Thursday, August 11, 2022 Time: 5:00 p.m. ET (2:00 p.m. PT) Live call: (877) 445-9755 (U.S. toll-free) or (201) 493-6744 Webcast (live and archived): https://evofem.investorroom.com/Update or https://www.webcast-eqs.com/register/evofem2022811/en Please connect to the webcast at least 15 min
-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Date: Thursday, August 4, 2022 Time: 5:00 pm. ET (2:00pm. PT) Live call: (800) 285-6670 (U.S. toll-free) or (713) 481-1320 Webcast (live and archived) and related slide presentation:
-- Double digit growth in net revenues over Q4 2021 -- -- Reduced selling and marketing costs 49% and total operating expense 19% vs. Q4 2021 -- -- Decreased loss from operations for the third consecutive quarter -- -- On track to report top-line Phase 3 data for the prevention of chlamydia and gonorrhea in 2H 2022 -- -- Conference call scheduled for 4:30 p.m. ET Today -- SAN DIEGO, May 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2022. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Bioscien
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
DEF 14A - Aditxt, Inc. (0001726711) (Filer)
PRER14A - Aditxt, Inc. (0001726711) (Filer)
8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K/A - Aditxt, Inc. (0001726711) (Filer)
424B3 - Aditxt, Inc. (0001726711) (Filer)
EFFECT - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
PRER14A - Aditxt, Inc. (0001726711) (Filer)
S-1/A - Aditxt, Inc. (0001726711) (Filer)
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for millions of women — SAN DIEGO, June 27, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM) today announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman's unique needs, to offer Phexxi® (lactic acid, citric acid and potassium bitartrate), the non-hormonal prescription vaginal gel FDA-approved to prevent pregnancy for those who choose to use an on-demand method of birth control.
-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States -- SAN DIEGO, June 11, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"
SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,186 shares of the Company's Series C-1 Convertible Preferred Stock, 4,186 shares of the Company's D-1 Preferred Stock, and warrants to purchase approximately 1.65 million shares of common stock in a private placement priced at-the-market under Nasdaq rules. The shares of Series C-1 Convertible Preferred Stock have a stated value of $1,000 per share. They are initially convertible into an aggregate of approximately 1.65 million
-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States -- SAN DIEGO, April 18, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agreement, Aditxt's wholly owned subsidiary, A
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Aditxt Inc. (NASDAQ:ADTX) ("Aditxt"), a Richmond, Virginia- b
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe
— Medi-Cal serves more than 15.4 million Californians — — 7.4% improvement in Phexxi rebate to take effect July 1, 2024 — SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
-- New weight loss drugs like Ozempic, Wegovy and Zepboundmay make oral birth control pills less effective at certain points -- SAN DIEGO, March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.
- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio --- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,186 shares of the Company's Series C-1 Convertible Preferred Stock, 4,186 shares of the Company's D-1 Preferred Stock, and warrants to purchase approximately 1.65 million shares of common stock in a private placement priced at-the-market under Nasdaq rules.The shares of Series C-1 Convertible Preferred Stock have a stated value of $1,000 per share. They are initially convertible into an aggregate of approximately 1.65 million sha
-8-K
Shares of Stryve Foods, Inc. (NASDAQ:SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods posted adjusted loss of $1.90 per share, versus market estimates for a loss of $1.96 per share. The company’s sales came in at $2.887 million versus expectations of $5.009 million, according to data from Benzinga Pro. Stryve Foods shares dipped 25.2% to $1.0965 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers VivoPower International PLC (NASDAQ:VVPR) shares surged 315% to $6.10 after the company's Tembo subsidiary announced it will merge with the Nasdaq-listed Cactus Acquisition Corp. 1 Limited. Trio Petroleum Corp. (
Aditxt, Inc. (NASDAQ:ADTX) shares are volatile Tuesday after the company announced it will acquire Appili Therapeutics. The Details: Aditxt’s wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction. Appili has developed FDA-approved Likmez (previously ATI-1501), its ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the U.S Department of Defense, and its ATI-1801 topical formulation targeting cutaneous leishmaniasis. Aditxt shares are moving on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 12 million shares have already been
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. MSP Recovery (NASDAQ:LIFW) shares moved upwards by 33.26% to $0.89. The market value of their outstanding shares is at $13.1 million. Aditxt (NASDAQ:ADTX) shares increased by 19.09% to $3.79. The market value of their outstanding shares is at $6.3 million. Q32 Bio (NASDAQ:QTTB) shares increased by 17.69% to $21.18. The company's market cap stands at $252.7 million. Evaxion Biotech (NASDAQ:EVAX) stock rose 16.4% to $3.76. The market value of their outstanding shares is at $18.0 million. As per the news, the Q4 earnin
Under the terms of the Arrangement Agreement, shareholders of Appili (the "Appili Shareholders") will receive (i) 0.002745004 of a share of common stock (each whole share, an "Aditxt Share") of Aditxt (the "Share Consideration") and (ii) US$0.0467 (or approximately CAD$0.0633 with reference to the Bank of Canada closing exchange rate on March 29, 2024) for each Appili Share held (the "Cash Consideration" and together with the Share Consideration collectively, the "Transaction Consideration") representing implied total consideration per Appili Share of approximately US$0.0561(or approximately CAD$0.07598 with reference to the Bank of Canada closing exchange rate on March 29, 2024) based on th